Overdose, Abuse, Misuse and Off-Label Use: Handling Special Situations in Pharmacovigilance

Not every pharmacovigilance report describes a medicine used as authorised. Overdose, abuse, misuse, off-label use and occupational exposure are what EU guidance calls “special situations” — and they are one of the areas where case-handling SOPs most often diverge from what Good Pharmacovigilance Practices (GVP) actually expects. Getting them right protects both submission compliance and the quality of the safety data that feeds signal detection and periodic reports.

What counts as a special situation

GVP Module VI, the EU guideline on the collection, management and submission of reports of suspected adverse reactions, groups together several circumstances that need specific handling beyond a standard adverse reaction report. Alongside exposure during pregnancy and breastfeeding, use in children or older people, and lack of therapeutic efficacy, it covers reports of:

  • Overdose — administration of a quantity per dose or cumulatively above the maximum recommended dose in the product information.
  • Abuse — persistent or sporadic, intentional excessive use, accompanied by harmful physical or psychological effects.
  • Misuse — intentional and inappropriate use not in accordance with the authorised product information.
  • Off-label use — intentional use for a medical purpose outside the terms of the marketing authorisation, for example a different indication, dose, route or population.
  • Medication error — an unintended failure in the treatment process that leads to, or could lead to, harm.
  • Occupational exposure — exposure to a medicine as a result of a person’s professional or non-professional occupation, such as a nurse handling a cytotoxic product.

The distinctions matter. Intent separates misuse and off-label use from medication errors, and a clinical purpose separates off-label use from misuse. Inconsistent classification makes aggregate data hard to interpret.

The reporting rule most often misapplied

The central point is simple: a special situation with an associated suspected adverse reaction is a valid individual case safety report (ICSR) and must be submitted to EudraVigilance within the usual timelines — 15 days for serious and 90 days for non-serious cases. A special situation without any associated adverse reaction is not an ICSR and should not be submitted as one.

That does not mean it can be discarded. Reports without adverse reactions should still be recorded in the safety database, followed up where relevant, and taken into account in periodic safety update reports (PSURs) and risk management. Two common failures follow from misreading this rule:

  • Over-submission — sending non-case reports of overdose or off-label use as ICSRs, which creates noise and can trigger questions from authorities.
  • Under-recording — closing special situation reports without logging them, leaving gaps in PSUR sections on misuse, abuse and off-label patterns.

Where special situations surface

These reports rarely arrive neatly labelled. They emerge from medical information enquiries, patient support programmes, market research, social media monitoring, literature screening and spontaneous reports from healthcare professionals. Each intake channel needs clear triage questions so staff can recognise, for instance, that a query about using a product in an unlicensed age group may be an off-label use report rather than just a medical information request.

MedDRA offers dedicated terms for overdose, abuse, misuse, off-label use and occupational exposure, and these should be coded consistently so that special situations are retrievable for signal detection and aggregate review.

Why it matters for signals and risk management

Patterns in special situations are often early indicators of a problem: repeated dosing errors may point to confusing packaging, rising misuse may justify additional risk minimisation, and widespread off-label use may need evaluation in the PSUR or the risk management plan. Products with abuse potential, narrow therapeutic windows or complex administration deserve particular attention, and pharmacovigilance inspectors routinely examine how these reports are captured.

How PQRA helps

PQRA supports marketing authorisation holders in Greece and across the EU with case-handling SOPs and intake checklists aligned to GVP Module VI, training for medical information and local safety staff, MedDRA coding conventions for special situations, and integration of these data into PSURs, risk management plans and signal detection. We also review existing processes ahead of pharmacovigilance inspections.

Want to check how your organisation handles special situation reports? Contact PQRA to discuss a review of your pharmacovigilance case-handling process.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *